Migraine Newswire (Page 7)

Migraine Newswire (Page 7)

Comprehensive Real-Time News Feed for Migraine. (Page 7)

Results 121 - 140 of 3,136 in Migraine

  1. When sleeping in separate rooms could save your marriageRead the original story w/Photo

    Jan 28, 2017 | Vanguard

    ... s and neck for five minutes to relieve any tension, is sufficient." Similarly, keeping a diary can help to identify migraine triggers and avoid

    Comment?

  2. Redhill Biopharma Ltd. (RDHL) Raised to Buy at Zacks Investment ResearchRead the original story w/Photo

    Jan 25, 2017 | Daily Political

    Zacks Investment Research currently has $12.00 price target on the stock. According to Zacks, "RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer.

    Comment?

  3. Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run...Read the original story w/Photo

    Jan 24, 2017 | Insider Monkey

    ... free by clicking here or you can login if you are already a member. Acorda Therapeutics Inc (NASDAQ: ACOR ) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich as likely to give Eli Lilly and Co (NYSE: LLY ) severe competition ...

    Comment?

  4. Allergan Release: Pharma Continues Commitment To Future Of Headache...Read the original story

    Jan 22, 2017 | BioSpace

    ... potential drug targets, emerging new treatments, and the importance of patient advocacy. , Chair of the American Migraine Foundation and President of the International Headache Society. "We are inspired by our attendees' commitment to raising their ...

    Comment?

  5. Week In Review: WuXi AppTec Acquires HD Biosciences In China CRO TieupRead the original story w/Photo

    Jan 22, 2017 | Seeking Alpha

    ... formed a partnership with Switzerland's Applied Pharma Research to distribute Diclofenac, a patented treatment for migraine, in China, Hong Kong, Macao and Taiwan. APR's product is a powder for oral solution. So far, migraines are not a major ...

    Comment?

  6. Eli Lilly: How Does The CoLucid Deal Impact The Stock?Read the original story w/Photo

    Jan 20, 2017 | Seeking Alpha

    ... Lilly currently has emerging pain pipeline assets including galcanezumab , which offers prospective treatment for migraine and cluster headache. CoLucid's main promise lies in its oral migraine medication, lasmiditan , which could be near the point ...

    Comment?

  7. Redhill Bio-Adr (RDHL) Upgraded to Buy by Zacks Investment ResearchRead the original story w/Photo

    Jan 20, 2017 | IntersportsWire

    They currently have $12.00 price target on the stock. According to Zacks, "RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer.

    Comment?

  8. Global Migraine Report 2017: Analysis of Leading Geographies (US,...Read the original story

    Jan 20, 2017 | Customer Interaction Solutions

    Research and Markets has announced the addition of the "Global Migraine Epidemiology and Patient Flow Analysis - 2017" report to their offering. The results of the Migraine patients study are announced in this new report.

    Comment?

  9. Here's Why CoLucid Pharmaceuticals Inc Popped YesterdayRead the original story w/Photo

    Jan 19, 2017 | Fox News

    ... data from the study showed that lasmidtan succeeded in meeting both its primary and secondary endpoints as a migraine treatment. Patients who took lasmiditan demonstrated a statistically significant decline in headache pain at the two-hour point ...

    Comment?

  10. Renhe Group and APR Applied Pharma Resea ...Read the original story

    Jan 19, 2017 | The Financial Mirror

    BEIJING & BALERNA, Switzerland-- -- APR Applied Pharma Research s.a. , the Swiss, independent developer of science driven, patent protected healthcare products, and Renhe Group, a Chinese leading pharmaceutical company, today are proud to announce the start of a partnership for the promotion, distribution and marketing of APR's patented Diclofenac powder for oral solution for migraine treatment, in China, Hong Kong, Macao and Taiwan. Migraine prevalence in China is rapidly growing due to the increasing population of patients affected in combination with the swift change of the society towards a modern industrialized country lifestyle, thus making the anti-migraine drugs market potential attractive.

    Comment?

  11. Renhe Group , APR Applied Pharma Research S.A. Release: Companies...Read the original story

    Jan 18, 2017 | BioSpace

    Renhe Group , APR Applied Pharma Research S.A. Release: Companies Announce A License Agreement For The Distribution In The Chinese Market Of An Innovative Solution To Treat Migraine BEIJING & BALERNA, Switzerland-- --APR Applied Pharma Research s.a. , the Swiss, independent developer of science driven, patent protected healthcare products, and Renhe Group, a Chinese leading pharmaceutical company, today are proud to announce the start of a partnership for the promotion, distribution and marketing of APR's patented Diclofenac powder for oral solution for migraine treatment, in China, Hong Kong, Macao and Taiwan.

    Comment?

  12. Renhe Release: Company Partners With Applied Pharma To Market Migraine Drug In ChinaRead the original story

    Jan 18, 2017 | BioSpace

    January 19, 2017 -- Renhe Group of Beijing has formed a partnership with Switzerland's Applied Pharma Research to distribute Diclofenac, a patented treatment for migraine, in China, Hong Kong, Macao and Taiwan. APR's product is a powder for oral solution.

    Comment?

  13. Exercise-Induced Headaches: Prevention, Management, and TreatmentRead the original story w/Photo

    Jan 19, 2017 | US Pharmacist

    ... migraines, especially in men. Although the diagnosis of primary exercise headache remains distinct from that of migraine, these two conditions often share similar characteristics, such as nausea, vomiting, scotomas, and photophobia.1,6 If a patient ...

    Comment?

  14. Renhe Group and APR Applied Pharma Research Announce a License...Read the original story

    Jan 19, 2017 | Customer Interaction Solutions

    Renhe Group and APR Applied Pharma Research Announce a License Agreement for the Distribution in the Chinese Market of an Innovative Solution to Treat Migraine APR Applied Pharma Research s.a. , the Swiss, independent developer of science driven, patent protected healthcare products, and Renhe Group, a Chinese leading pharmaceutical company, today are proud to announce the start of a partnership for the promotion, distribution and marketing of APR's patented Diclofenac powder for oral solution for migraine treatment, in China, Hong Kong, Macao and Taiwan.

    Comment?

  15. Lilly announces plan for new migraine drugRead the original story w/Photo

    Jan 18, 2017 | WTHR-TV Indianapolis

    Eli Lilly and Company announced plans today to provide a new migraine drug for patients through the purchase of a company called CoLucid. In 2014, Indianapolis-based Lilly announced a strategic plan to bring 20 drugs to market in 10 years.

    Comment?

  16. Why Fastenal, Mead Johnson Nutrition, and CoLucid Pharmaceuticals Jumped TodayRead the original story w/Photo

    Jan 18, 2017 | Fox News

    ... terms of the deal, CoLucid shareholders will receive $46.50 per share in cash. Interestingly, CoLucid's lasmiditan migraine drug was initially discovered at Lilly, but CoLucid licensed the drug 12 years ago. Now that Lilly's priorities have changed, ...

    Comment?

  17. Lilly to buy migraine-drug maker for $960 millionRead the original story w/Photo

    Jan 18, 2017 | USA Today

    Lilly to buy migraine-drug maker for $960 million CoLucid is in the final stages of testing a new migraine medicine. Check out this story on USATODAY.com: http://usat.ly/2k0lIm4 Indianapolis-based Eli Lilly and Co.

    Comment?

  18. Lilly to Acquire CoLucid PharmaRead the original story w/Photo

    Jan 18, 2017 | Contract Pharma Breaking News

    ... CoLucid for approximately $960 million in cash. The acquisition enhances Lilly's portfolio in pain management for migraine with a potential near-term launch. The transaction is expected to close by 1Q17, subject customary closing conditions. CoLucid ...

    Comment?

  19. UPDATE 3-Lilly builds migraine arsenal with $960 mln CoLucid buyRead the original story w/Photo

    Jan 18, 2017 | Reuters

    CoLucid's lasmiditan, which has already succeeded in one late-stage trial for acute migraine relief, was licensed to the company by Lilly in 2005. Lilly, whose migraine-prevention therapy is in late-stage development, has offered $46.50 per CoLucid share in cash, a rich premium of about 33 percent to CoLucid's Tuesday close.

    Comment?

  20. Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech MoversRead the original story w/Photo

    Jan 18, 2017 | TheStreet.com

    CoLucid Pharmaceuticals led the biotech stocks Wednesday morning in premarket moving, seeing its share price skyrocket more than 30% ahead of market's open. CoLucid, which is developing a pill to treat migraine headaches, is being acquired by Eli Lilly for $960 million in cash.

    Comment?